AQSTAquestive Therapeutics, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · aquestive.com

4.660USD+1.53%Mkt Cap: 584.88M $P/E: —3d ago

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a su…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$65.19BUSDP/E 23.7

TAK

Takeda Pharmaceutical Co. Ltd.

$58.06BUSD

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

$43.98BUSDP/E 20.4

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation

Swedish Orphan Biovitrum AB

Neurocrine Biosciences, Inc.

$15.51BUSDP/E 22.3

ELAN

Elanco Animal Health Incorporat

$11.98BUSD

RDY

Dr. Reddy's Laboratories Ltd

Hims & Hers Health, Inc.

$7.88BUSD

LNTH

Lantheus Holdings Inc

$6.53BUSDP/E 23.9

AMRX

Amneal Pharmaceuticals, Inc. Class A

Kiniksa Pharmaceuticals, Ltd.

$6.08BUSDP/E 79.8

Key Statistics

Company

Market Cap584.88M $

Enterprise Value524.72M $

Revenue (TTM)54.09M $

Gross Profit25.99M $

Net Income (TTM)-83.78M $

Revenue/Share0.4500 USD

Last Price4.660 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees147

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-7.89

PEG—

EV/EBITDA-10.05

EV/Revenue9.70

P/S10.43

P/B-9.97

EPS (TTM)-0.65

EPS (Forward)-0.57

52W Range

2.93037% of range7.550

52W High7.550 USD

52W Low2.930 USD

Profitability

Gross Margin58.35%

Oper. Margin-59.51%

EBITDA Margin-96.51%

Profit Margin-188.09%

ROE248.90%

ROA-52.23%

Growth

Revenue Growth38.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-52.43M $

CapEx (TTM)562.00K $

FCF Margin-49.72%

FCF Yield-4.60%

Net Debt-39.46M $

Net Debt/EBITDA0.76

Balance Sheet

Debt/Equity-1.26

Current Ratio7.19

Quick Ratio6.54

Book Value/Sh-0.4510 USD

Cash/Share0.7850 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.2 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)9.333 USD

Upside (mean)+100.3%

Target Range6.000 USD – 11.00 USD

$6.000+100.3% to mean$11.00

# Analysts9

Ownership

Shares Out.125.51M

Float114.66M

Insiders2.84%

Institutions58.63%

Short Interest

Short Ratio10.0d

Short % Float15.06%

Short % Out.14.38%

Shares Short18.05M

Short (prev mo.)16.00M

Technical

SMA 504.157 (+12.1%)

SMA 2004.503 (+3.5%)

Beta1.43

S&P 52W Chg18.16%

Avg Vol (30d)2.89M

Avg Vol (10d)5.27M

Technical Indicators

RSI (14)68.5

MACD0.1223

MACD Signal0.0327

MACD Hist.+0.0896

BB Upper4.668 USD

BB Middle4.003 USD

BB Lower3.339 USD

BB Width33.19%

ATR (14)0.2502 USD

Vol Ratio (20d)0.58x